Who are Roflumilast Cream 0.3%'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): metformin and roflumilast.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/roflumilast-cream-0-3.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Roflumilast Cream 0.3% — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Roflumilast Cream 0.3% (Roflumilast Cream 0.3%) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Phosphodiesterase-4 inhibitor. Area: Respiratory.

phase 3 Phosphodiesterase-4 inhibitor Phosphodiesterase-4 Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Roflumilast Cream 0.3% (Roflumilast Cream 0.3%) — Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. Roflumilast is a phosphodiesterase-4 inhibitor, which reduces inflammation by inhibiting the production of pro-inflammatory cytokines.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Roflumilast Cream 0.3% TARGET	Roflumilast Cream 0.3%	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	phase 3	Phosphodiesterase-4 inhibitor	Phosphodiesterase-4
metformin and roflumilast	metformin and roflumilast	University Medical Centre Ljubljana	marketed	Combination therapy: biguanide and phosphodiesterase-4 inhibitor	Metformin: mitochondrial glycerophosphate dehydrogenase; Roflumilast: phosphodiesterase-4 (PDE-4)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Phosphodiesterase-4 inhibitor class)

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · 1 drug in this class
Pfizer Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Roflumilast Cream 0.3% — Competitive Intelligence Brief. https://druglandscape.com/ci/roflumilast-cream-0-3. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab